Valuation: Ipca Laboratories Limited

Market Cap 503B 5.29B 4.75B 4.38B 3.98B 7.43B 7.52B 52.57B 20.88B 263B 19.86B 19.43B 835B P/E 2027 *
33.1x
P/E 2028 * 28.2x
Enterprise Value 492B 5.18B 4.65B 4.29B 3.89B 7.27B 7.36B 51.45B 20.43B 258B 19.44B 19.02B 818B EV / Sales 2027 *
4.48x
EV / Sales 2028 * 3.93x
Free-Float
54.94%
Yield 2027 *
0.29%
Yield 2028 * 0.31%
1 day+2.18%
1 week+9.17%
Current month+2.79%
1 month+0.51%
3 months+12.37%
6 months+27.31%
Current year+39.60%
1 week 1,797.6
Extreme 1797.6
1,994
1 month 1,797
Extreme 1797
1,994
Current year 1,391.8
Extreme 1391.8
2,038
1 year 1,268
Extreme 1268
2,038
3 years 966.4
Extreme 966.4
2,038
5 years 669.8
Extreme 669.8
2,038
10 years 200
Extreme 200
2,038
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 53 11/11/2008
Director/Board Member 70 01/08/1994
Date Insider Type Main position Quantity % Market Cap. Importance
12/19/24 A Sell 4,000,000 1.5766%
Change 5-day change 1-year change 3-year change Capi.($)
+2.18%+9.17%+56.13%+102.17% 5.17B
+0.22%-0.14%+55.12%+128.82% 1,140B
+0.91%+3.61%+41.21%+84.57% 641B
-0.12%-0.93%+25.59%+106.14% 507B
+0.63%+2.33%+49.21%+67.82% 383B
+0.86%-4.37%+61.16%+37.93% 347B
+1.02%+1.80%+24.84%+53.75% 293B
-0.25%+1.62%+2.20%+26.65% 266B
+0.75%+2.05%+53.85%+71.25% 240B
+0.25%+1.64%+32.05%+107.62% 197B
Average +0.65%+3.32%+40.14%+78.67% 401.9B
Weighted average by Cap. +0.44%+2.99%+42.22%+88.49%

Financials

2027 *2028 *
Net sales 110B 1.16B 1.04B 959M 869M 1.63B 1.65B 11.5B 4.57B 57.6B 4.34B 4.25B 183B 123B 1.29B 1.16B 1.07B 971M 1.81B 1.84B 12.84B 5.1B 64.32B 4.85B 4.75B 204B
Net income 15.12B 159M 143M 132M 120M 224M 226M 1.58B 628M 7.93B 598M 585M 25.13B 17.9B 188M 169M 156M 142M 265M 268M 1.87B 743M 9.38B 707M 692M 29.75B
Net Debt -10.65B -112M -101M -92.92M -84.26M -157M -159M -1.11B -442M -5.58B -421M -412M -17.7B -19.96B -210M -189M -174M -158M -295M -299M -2.09B -829M -10.46B -789M -772M -33.17B
Projected Income Statement - Annual - Ipca Laboratories Limited
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
27/10/26 ₹1,980.80 +2.18% 189,254
26/10/26 ₹1,938.60 -0.75% 332,626
23/10/26 ₹1,953.30 +2.62% 318,781
22/10/26 ₹1,903.50 -0.80% 327,011
21/10/26 ₹1,918.90 +5.75% 511,090
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Ipca Laboratories Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,980.80INR
Average target price
1,981.72INR
Spread / Average Target
+0.05%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipca Laboratories Limited
  1. Stock Market
  2. Stocks
  3. IPCALAB Stock